60 Degrees Pharmaceuticals Announces Clinical and Molecular Results for Babesiosis Study

Article summary

60 Degrees Pharmaceuticals reported initial clinical and molecular data from the first five patients in its expanded access study of tafenoquine for relapsing babesiosis.